Treatment of stages II, III and IV primary surface epithelial ovarian cancers by maximum bulk tumour reduction and combined chemotherapy with cyclophosphamide, doxorubicin and cisplatin.
Forty-six patients with Stages II, III and IV ovarian cancer received treatment with cyclophosphamide, doxorubicin and cisplatin. Patient response to therapy was assessed 6 weeks after the cessation of therapy. Thirty-three patients (72%) were in complete response and six (13%) had a partial response to treatment. No relationship was found between the age of the patient, histologic type or grade of tumour and survival, although stage and initial debulking were important. Treatment had to be discontinued in 11 patients because of progression of the disease or serious side-effects. The probability of survival beyond 24 months for all patients was 71% and the mean survival overall was 32 months.
S
S
Khanna
P
P
Kirwan
N J
NJ
Naftalin
R J
RJ
Aukett
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011336:Probability
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin